{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:50:40Z","timestamp":1788184240478,"version":"build-2803163510"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>In response to the limitations of traditional therapies for immune and infectious skin diseases in terms of tissue penetration, cost, and drug resistance, nanobodies derived from camelids and containing only a single heavy chain variable domain have shown significant advantages: their small molecular weight ensures excellent skin penetration ability, the extended CDR3 domain enables precise targeting of hidden epitopes, and they have excellent stability (tolerance to extreme pH, temperature, protease) and low-cost production potential. In the treatment of immune skin diseases, nanobodies effectively synergistically block key inflammatory pathways through multivalent\/multispecific design, demonstrating deep therapeutic effects beyond some traditional therapies in areas such as psoriasis, atopic dermatitis, and hidradenitis suppurativa. In the field of infectious skin diseases, it effectively blocks the process of pathogen infection by efficiently neutralizing key virulence factors (such as invasion proteins, adhesion factors, toxins) of viruses, bacteria, fungi, and parasites, and has the potential to serve as a highly specific diagnostic tool. Future research and development will focus on multi-target optimization, artificial intelligence assisted design, new transdermal\/long-acting delivery systems, and precision medicine strategies, promoting nanobodies as an efficient and precise solution to revolutionize the treatment of skin diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1705553","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:36:03Z","timestamp":1765348563000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Research progress on the application of nanobodies in immunity and infectious skin diseases"],"prefix":"10.3389","volume":"16","author":[{"given":"Liguo","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.4274\/balkanmedj.galenos.2024.2024-1-96","article-title":"Thymic stromal lymphopoietin activates mouse dendritic cells through the JAK\/SYK pathway in promoting Th17 response in psoriasis","author":"Song","year":"2024","journal-title":"Balkan Med J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2016.10.019","article-title":"Camelid and shark single domain antibodies: structural features and therapeutic potential","volume":"45","author":"Konning","year":"2017","journal-title":"Curr Opin Struct Biol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J Nanobiotechnology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.3390\/ijms24065994","article-title":"NANOBODIES\u00ae: A review of diagnostic and therapeutic applications","volume":"24","author":"Jin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01182","article-title":"Nanobodies: next generation of cancer diagnostics and therapeutics","volume":"10","author":"Yang","year":"2020","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/j.drudis.2018.06.003","article-title":"Therapeutic application of antibody fragments in autoimmune diseases: current state and prospects","volume":"23","author":"Fernandes","year":"2018","journal-title":"Drug Discov Today"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40259-019-00392-z","article-title":"The therapeutic potential of nanobodies","volume":"34","author":"Jov\u010devska","year":"2020","journal-title":"BioDrugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100865","DOI":"10.1016\/j.mcpro.2024.100865","article-title":"Nanobodies: from high-throughput identification to therapeutic development","volume":"23","author":"Fridy","year":"2024","journal-title":"Mol Cell Proteomics"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2341443","DOI":"10.1080\/19420862.2024.2341443","article-title":"Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions","volume":"16","author":"Mullin","year":"2024","journal-title":"MAbs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21617","article-title":"Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence","volume":"187","author":"Reich","year":"2022","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/bit.28816","article-title":"Advancements in nanobody generation: Integrating conventional, in silico, and machine learning approaches","volume":"121","author":"Reddy","year":"2024","journal-title":"Biotechnol Bioeng"},{"key":"B12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1186\/s12967-025-06723-9","article-title":"IL-17A inhibitors modulate skin microbiome in psoriasis: implications for microbial homeostasis","volume":"23","author":"Lv","year":"2025","journal-title":"J Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2025.05.005","article-title":"Novel therapeutic targets in the management of psoriatic disease","volume":"51","author":"Childs","year":"2025","journal-title":"Rheum Dis Clin North Am"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2025.2500292","article-title":"Assessing the clinical progress of the bispecific nanobody sonelokimab","volume":"34","author":"Dogra","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2443538","DOI":"10.1080\/19420862.2024.2443538","article-title":"Antibodies to watch in 2025","volume":"17","author":"Crescioli","year":"2025","journal-title":"MAbs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14861","article-title":"Topical application of a novel anti-interleukin-17A antibody fragment penetrates psoriatic skin: Results of a randomised, double-blind, placebo-controlled Phase Ib study","volume":"32","author":"Sinclair","year":"2023","journal-title":"Exp Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00928-w","article-title":"Next-generation anti-IL-17 agents for psoriatic disease: A pipeline review","volume":"26","author":"Kim","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"364086422","DOI":"10.1177\/20406223211037846","article-title":"Dual inhibition of IL-17A and IL-17F in psoriatic disease","volume":"12","author":"Iznardo","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03971-6","article-title":"Sonelokimab, an IL-17A\/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial","author":"McInnes","year":"2025","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"adv43685","DOI":"10.2340\/actadv.v105.43685","article-title":"Adverse events and immune response in psoriasis patients receiving interleukin-17 inhibitors","volume":"105","author":"Schwarz","year":"2025","journal-title":"Acta Derm Venereol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186455","article-title":"Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies","volume":"14","author":"Brembilla","year":"2023","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/PTT.S212774","article-title":"Serum TSLP is a potential biomarker of psoriasis vulgaris activity","volume":"9","author":"El-Ghareeb","year":"2019","journal-title":"Psoriasis (Auckl)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.idoj_742_23","article-title":"A comparative study on serum levels of \u201cThymic stromal lymphopoietin\u201d Between patients with psoriasis vulgaris and healthy individuals: A case-control study","volume":"15","author":"Kollabathula","year":"2024","journal-title":"Indian Dermatol Online J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00005-023-00685-w","article-title":"Improved production of anti-FGF-2 nanobody using Pichia pastoris and its effect on antiproliferation of keratinocytes and alleviation of psoriasis","volume":"71","author":"Zhou","year":"2023","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.10.023","article-title":"Novel insights into atopic dermatitis","volume":"151","author":"Schuler","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/exd.13942","article-title":"Translational drug discovery and development with the use of tissue-relevant biomarkers: Towards more physiological relevance and better prediction of clinical efficacy","volume":"29","author":"Florian","year":"2020","journal-title":"Exp Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"133957","DOI":"10.1016\/j.ijbiomac.2024.133957","article-title":"Structural insights into the binding of nanobodies to the Staphylococcal enterotoxin B","volume":"276","author":"Zong","year":"2024","journal-title":"Int J Biol Macromolecules"},{"key":"B29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s12010-018-2762-y","article-title":"Rapid and sensitive detection of staphylococcal enterotoxin B by recombinant nanobody using phage display technology","volume":"187","author":"Zanganeh","year":"2019","journal-title":"Appl Biochem Biotechnol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02475-9","article-title":"Hidradenitis suppurativa","volume":"405","author":"Sabat","year":"2025","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"100483","DOI":"10.1016\/j.jacig.2025.100483","article-title":"Combined TNF-alpha and OX40L targeting as a new treatment option for hidradenitis suppurativa","volume":"4","author":"Leeuw","year":"2025","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B32","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13075-015-0651-0","article-title":"The preclinical pharmacology of the high affinity anti-IL-6R Nanobody\u00ae ALX-0061 supports its clinical development in rheumatoid arthritis","volume":"17","author":"Van Roy","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-023-00774-8","article-title":"Cutaneous lupus erythematosus: an update on pathogenesis and future therapeutic directions","volume":"24","author":"Niebel","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01802","article-title":"Single-domain antibodies as therapeutics against human viral diseases","volume":"8","author":"Wu","year":"2017","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.1038\/s41467-025-58669-7","article-title":"A potent protective bispecific nanobody targeting Herpes simplex virus gD reveals vulnerable epitope for neutralizing","volume":"16","author":"Hu","year":"2025","journal-title":"Nat Commun"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s42003-025-08494-x","article-title":"Bivalent single-domain antibodies show potent mpox virus neutralization through M1R antigen","volume":"8","author":"Akazawa","year":"2025","journal-title":"Commun Biol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41421-025-00771-7","article-title":"Identification of neutralizing nanobodies protecting against poxvirus infection","volume":"11","author":"Yang","year":"2025","journal-title":"Cell Discov"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S431619","article-title":"Screening, expression and identification of nanobody against monkeypox virus A35R","volume":"18","author":"Meng","year":"2023","journal-title":"Int J Nanomedicine"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16697","article-title":"Recent advances in cutaneous HPV infection","volume":"50","author":"Shimizu","year":"2023","journal-title":"J Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0311137","article-title":"Design and antiviral assessment of a panel of fusion proteins targeting human papillomavirus type 16","volume":"19","author":"Bai","year":"2024","journal-title":"PloS One"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.7705\/biomedica.5797","article-title":"Rediscovering the chikungunya virus","volume":"41","author":"Calvo","year":"2021","journal-title":"Biomedica"},{"key":"B42","doi-asserted-by":"publisher","first-page":"105446","DOI":"10.1016\/j.antiviral.2022.105446","article-title":"Inhibition of Chikungunya virus early replication by intracellular nanoantibodies targeting nsP2 Epitope Rich Region","volume":"208","author":"Deng","year":"2022","journal-title":"Antiviral Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.04.007","article-title":"Skin immunity to candida albicans","volume":"37","author":"Kashem","year":"2016","journal-title":"Trends Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.03409-23","article-title":"Nanobody-mediated neutralization of candidalysin prevents epithelial damage and inflammatory responses that drive Vulvovaginal candidiasis pathogenesis","volume":"15","author":"Valentine","year":"2024","journal-title":"mBio"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04269-23","article-title":"The development of single-domain VHH nanobodies that target the Candida albicans cell surface","volume":"12","author":"Buda De Cesare","year":"2024","journal-title":"Microbiol Spectr"},{"key":"B46","doi-asserted-by":"publisher","first-page":"129208","DOI":"10.1016\/j.ijbiomac.2024.129208","article-title":"Development of nanobodies specific to clumping factors A of Staphylococcus aureus by yeast surface display","volume":"259","author":"Mei","year":"2024","journal-title":"Int J Biol Macromolecules"},{"key":"B47","doi-asserted-by":"publisher","first-page":"104927","DOI":"10.1016\/j.jbc.2023.104927","article-title":"Targeting hemoglobin receptors IsdH and IsdB of Staphylococcus aureus with a single VHH antibody inhibits bacterial growth","volume":"299","author":"Valenciano-Bellido","year":"2023","journal-title":"J Biol Chem"},{"key":"B48","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/s42003-021-02357-x","article-title":"Structural basis of inhibition of a transporter from Staphylococcus aureus, NorC, through a single-domain camelid antibody","volume":"4","author":"Kumar","year":"2021","journal-title":"Commun Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.0c00422","article-title":"Nanobodies based on a sandwich immunoassay for the detection of staphylococcal enterotoxin B free from interference by protein A","volume":"68","author":"Ji","year":"2020","journal-title":"J Agric Food Chem"},{"key":"B50","doi-asserted-by":"publisher","first-page":"107927","DOI":"10.1016\/j.intimp.2021.107927","article-title":"Liposome-based nanocarriers loaded with anthrax lethal factor and armed with anti-CD19 VHH for effectively inhibiting MAPK pathway in B cells","volume":"100","author":"Banihashemi","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/pim.12718","article-title":"Camel nanobodies: Promising molecular tools against leishmaniasis","volume":"42","author":"Abu Alshamat","year":"2020","journal-title":"Parasite Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2091215291","DOI":"10.1177\/15330338211010117","article-title":"Nanobody conjugates for targeted cancer therapy and imaging","volume":"20","author":"Kang","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"B53","doi-asserted-by":"publisher","first-page":"9778","DOI":"10.3390\/ijms22189778","article-title":"Nanobodies enhancing cancer visualization, diagnosis and therapeutics","volume":"22","author":"Naidoo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2023.09.005","article-title":"A PD-L1xCD3 bispecific nanobody as a novel T-cell engager in treating PD-L1 overexpression melanoma","volume":"163","author":"Li","year":"2023","journal-title":"Mol Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e1506","DOI":"10.1002\/wnan.1506","article-title":"Immunoengineering with biomaterials for enhanced cancer immunotherapy","volume":"10","author":"Xie","year":"2018","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1705553\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T06:36:03Z","timestamp":1765348563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1705553\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":55,"alternative-id":["10.3389\/fimmu.2025.1705553"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1705553","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"article-number":"1705553"}}